Clinical Trial Update: Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating PPI-1019 in patients with mild-to-moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PPI-1019 (PPI-1019)

Snippet

Sponsor: PRAECIS Pharmaceuticals Inc. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED